The association of ideal cardiovascular health and its change with subclinical atherosclerosis according to glucose status: A prospective cohort study
Xiaojing Jia,Yilan Ding,Chunyan Hu,Hong Lin,Lin Lin,Xueyan Wu,Hongyan Qi,Shuangyuan Wang,Ruizhi Zheng,Jie Zheng,Min Xu,Yu Xu,Tiange Wang,Zhiyun Zhao,Yuhong Chen,Mian Li,Guang Ning,Weiqing Wang,Weiguo Hu,Yufang Bi,Jieli Lu
DOI: https://doi.org/10.1111/1753-0407.70007
IF: 4.53
2024-10-12
Journal of Diabetes
Abstract:Highlights Participants with hyperglycemia who had high score of CVH exhibited no significant excess risk of subclinical atherosclerosis. Improvement in CVH during a median follow‐up of 4.3 years showed a beneficial effect on reduced risk of subclinical atherosclerosis in individuals with hyperglycemia, compared with those who had normal glucose regulation and stable CVH. Promoting the adherence to, and the improvement of, both healthy behaviors and factors was a key strategy to tackle the onset of atherosclerosis. Background An updated definition was developed to better evaluate cardiovascular health (CVH). We aimed to investigate whether optimal or improvement of six CVH metrics defined by new Life's Essential 8 (LE8) may counteract the risk of subclinical atherosclerosis among patients with hyperglycemia. Methods We conducted a prospective analysis of 5225 participants without prior cardiovascular diseases, of whom 4768 had complete data on CVH change. Subjects with CVH scores of 0–49, 50–79, and 80–100 points were categorized as having low, moderate, or high CVH, respectively. Subclinical atherosclerosis was evaluated by brachial‐ankle pulse wave velocity, pulse pressure and albuminuria, both separately and in combination. Results Of the 5225 participants, 1937 (37.1%) had normal glucose regulation, while 3288 (62.9%) had hyperglycemia. The multivariable‐adjusted odds ratio (OR) for composite subclinical atherosclerosis was 2.34 (95% confidence interval [CI], 1.88–2.91), 1.43 (95% CI, 1.21–1.70), and 0.74 (95% CI, 0.46–1.18), for participants with hyperglycemia who had low, moderate, or high overall CVH scores, respectively, compared with participants with normal glucose regulation. In addition, compared with those with stable CVH and normal glucose regulation, participants who exhibited greater improvements in overall CVH from 2010 to 2014 had a reduced risk of composite subclinical atherosclerosis with an OR of 0.72 (95% CI, 0.53–0.98) for those with normal glucose regulation, and 1.13 (95% CI, 0.87–1.48) for those with hyperglycemia. Conclusions The novel defined CVH using six metrics was inversely associated with subsequent risk of subclinical atherosclerosis. Both the status of CVH and its changes modified the relationship between hyperglycemia and subclinical atherosclerosis.
endocrinology & metabolism